A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

@article{Kuenen2010API,
  title={A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.},
  author={Bart C. Kuenen and Petronella Els O Witteveen and Rita Ruijter and Guiseppe Giaccone and Aruna Dontabhaktuni and Floyd Fox and Terry Katz and Hagop Youssoufian and Junming Zhu and Eric K. Rowinsky and Emile E Voest},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 6},
  pages={
          1915-23
        }
}
PURPOSE This study aimed to determine a maximum tolerated dose (MTD) and recommended dose for disease-directed studies of necitumumab (IMC-11F8), a fully human IgG(1) monoclonal antibody directed at the epidermal growth factor receptor, and to characterize the safety profile, pharmacokinetics, preliminary antitumor activity, and immunogenicity of necitumumab. EXPERIMENTAL DESIGN Patients with advanced solid malignancies were treated with 100 to 1,000 mg (flat dosing) necitumumab followed by a… CONTINUE READING
Highly Cited
This paper has 23 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations